Clinical and pathologic remission of pediatric ulcerative colitis with serum-derived bovine immunoglobulin added to the standard treatment regimen by Soriano, Rachelle A. & Ramos-Soriano, Asuncion G.
  
Rachelle A. Soriano, Asuncion G. Ramos-Soriano 
Clinical and pathologic remission of pediatric 
ulcerative colitis with serum-derived bovine 
immunoglobulin added to the standard 
treatment regimen 
 
Article (Published version) 
(Refereed) 
 
Original citation: Soriano, Rachelle A. and Ramos-Soriano, Asuncion G. (2017) Clinical and 
pathologic remission of pediatric ulcerative colitis with serum-derived bovine immunoglobulin added 
to the standard treatment regimen. Case Reports in Gastroenterology, 11 (2). pp. 335-343. ISSN 
1662-0631 
DOI: 10.1159/000475923 
 
 
Reuse of this item is permitted through licensing under the Creative Commons: 
 
© 2017 The Authors 
CC BY-NC 4.0 
 
This version available at: http://eprints.lse.ac.uk/83216/ 
Available in LSE Research Online: July 2017 
 
LSE has developed LSE Research Online so that users may access research output of the School. 
Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or 
other copyright owners. You may freely distribute the URL (http://eprints.lse.ac.uk) of the LSE 
Research Online website.  
 
 
 
  
Case Rep Gastroenterol 2017;11:335–343 
DOI: 10.1159/000475923 
Published online: May 19, 2017 
© 2017 The Author(s) 
Published by S. Karger AG, Basel 
www.karger.com/crg 
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 
International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes requires written permission. 
 
 
           
 
 Asuncion G. Ramos-Soriano, MD 
Pediatric Gastroenterology and Nutrition 
1710 E. Saunders Suite B 200 
Laredo, TX 78041 (USA) 
E-Mail agsoriano@gmail.com 
 
  
Single Case 
 
Clinical and Pathologic Remission of 
Pediatric Ulcerative Colitis with 
Serum-Derived Bovine 
Immunoglobulin Added to the 
Standard Treatment Regimen 
Rachelle A. Sorianoa    Asuncion G. Ramos-Sorianob     
a
Division of Global Health, The London School of Economics and Political Science, 
London, UK; 
b
Pediatric Gastroenterology and Nutrition, Doctors Hospital of Laredo, 
Laredo, TX, USA 
Keywords 
Pediatrics · Refractory ulcerative colitis · Medical food · Oral immunoglobulin 
Abstract 
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is particularly trouble-
some for pediatric patients, as current therapeutic options consist of biologic agents and 
steroids which alter the immune response and have the harmful side effect of leaving the 
patient more susceptible to opportunistic infections and eventual surgery. Another option for 
therapy exists in the form of serum-derived bovine immunoglobulin/protein isolate (SBI), the 
key ingredient in a medical food, EnteraGam
®
. The FDA has reviewed the safety of SBI and 
issued a no challenge letter to the generally recognized as safe (GRAS) findings for this med-
ical food. The product also has no known food or drug interactions, no significant adverse 
effects, and no contraindications, save for beef allergy. SBI has been shown to induce clinical 
remission in adult populations and to decrease markers of inflammation in pediatric patients. 
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Here, we present a detailed case of pediatric UC, including documentation of mucosal heal-
ing and decrease in pediatric UC activity index in a difficult to treat pediatric patient, after the 
addition of SBI to this patient’s treatment regimen. © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Ulcerative colitis (UC) is a chronic, often lifelong, inflammatory bowel disease (IBD) that 
affects over a quarter million children in the US [1]. It presents as a remitting and relapsing 
inflammation of the mucosal lining of varying extent from the rectum to the proximal colon. 
Affected patients present with crampy abdominal pain, diarrhea, bloody stools, and ulti-
mately growth and nutritional impairment. At least 30% of pediatric IBD patients also pre-
sent with extraintestinal manifestations within 15 years of diagnosis, and it has been report-
ed that the incidence of colorectal cancer in 10- to 14-year-old patients with UC is over 118 
times greater than that of the control population. The etiopathogenesis of UC is multifactori-
al with interplay of genetic, immunologic, and environmental factors. Classification of a pa-
tient’s disease severity using the Pediatric Ulcerative Colitis Activity Index (PUCAI) provides 
an appropriate guideline in the management of acute disease with use of second-line agents 
in those with increasing scores [2, 3]. The PUCAI defines disease severity with a combination 
of scores for abdominal pain, rectal bleeding, stool consistency, number of stools in 24 h, 
nocturnal stools, and activity level to assess disease activity. The score ranges from 0–85, 
with <10 indicating remission, 10–34 mild disease, 35–64 moderate disease, and 65–85 se-
vere disease (Table 1). Calcineurin inhibitors and biologic agents have been used in severe 
fulminant cases with the hopes of preventing surgery. However, their use has been associat-
ed with toxicities and side effects. Colectomy is warranted in those with life-threatening 
bleeding and perforation, and is the treatment of choice in patients who are refractory to 
medical management with long-standing disease and nutritional impairment. 
Adjunctive therapies for UC consist of antibiotics and probiotics. Both therapies pre-
sumably alter the gut microbiome as a means of controlling disease activity. There are lim-
ited studies on antibiotic efficacy in pediatric UC. Probiotics may aid in induction and 
maintenance of remission in UC and are also believed to decrease the secretion of inflamma-
tory cytokines as well as increase the secretion of anti-inflammatory cytokines, thereby en-
hancing the mucosal barrier. Several probiotic preparations have been studied in adult and 
pediatric UC. A medical food probiotic, VSL#3, appears to hold promise. 
Recently, the use of a therapeutic and non-probiotic medical food, serum-derived bovine 
immunoglobulin/protein isolate (SBI), has been shown to induce clinical and endoscopic 
remission with a markedly improved Mayo-UC score in an adult with long-standing refracto-
ry UC after 2 months of use [4]. Other adult IBD studies support similar results [5, 6]. A re-
cent case report of a 13-year-old pediatric UC patient has also been presented, demonstrat-
ing clinical and inflammatory remission based on complete disappearance of symptoms 
within 4 weeks and decreased fecal calprotectin from >1,700 to <15 μg/g after 3 months of 
SBI use when added to other standard treatments [7]. 
SBI in EnteraGam® consists of >90% protein, of which nearly 60% is immunoglobulin 
(>50% IgG, ~5% IgM, ~1% IgA) along with 5 g of dextrose to aid in dissolution of the protein 
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in liquids or soft food and trace amounts of the nonallergenic fat, sunflower lecithin, used in 
the spraying drying process of the product. The overall mechanism of SBI is postulated to 
involve binding to multiple microbial antigens such as lipopolysaccharide, flagellin, and Clos-
tridium difficile toxins A and B, aiding in the management of gut barrier function and immune 
balance by limiting antigen absorption [8, 9]. The initial binding event forms antibody-
antigen complexes that are effectively too large to translocate through damaged tight junc-
tions within the gut, thus removing a potential chronic trigger of inflammation and leading 
to an eventual restoration of gut homeostasis [8–10]. Despite its broad activity due to the 
variety of polyclonal antibodies present, SBI does not adversely affect commensal intestinal 
bacteria. Previous studies investigating the preparation have demonstrated its ability to 
reduce signs and symptoms of colitis in both animals and humans [4–7]. Thus, SBI was cho-
sen as an add-on therapy for pediatric UC in this case. 
Case Presentation 
We present the case of a 14-year-old, previously well Hispanic-American female teenag-
er. She complained of diffuse abdominal pain for 6 months prior to admission. Associated 
signs and symptoms consisted of 4.54 kg of weight loss associated with poor appetite, nau-
sea, and bloody, watery stools with mucus occurring more than 20 times daily. Her past 
medical history was unremarkable for chronic gastrointestinal disease or prior admission 
for severe gastrointestinal symptoms. She had a tonsillectomy at the age of 6 years. She had 
no chronic diseases, no history of frequent antibiotic intake, and no history of travel. Her 
deceased maternal grandmother had a vague history of colitis. She had lived in a United 
States border community all her life. 
Complete outpatient diagnostic workup by her pediatrician for intestinal parasites and 
bacterial pathogens was unremarkable. She was initially managed as a case of viral gastroen-
teritis with conservative measures. She was never febrile. However, the patient’s symptoms 
persisted with multiple school absences and progressive weight loss despite adherence to a 
bland diet. Her abdominal pain became progressively crampy with increasingly watery, 
bloody stools with mucus for which she was brought to the emergency room and was subse-
quently admitted for further evaluation by a pediatric gastroenterologist. 
Physical examination upon admission revealed normal temperature, mild tachycar- 
dia, and note of generalized pallor. Abdominal examination revealed slight abdominal dis-
tension with mild diffuse tenderness and sluggish bowel sounds. Her diagnostic laboratory 
workup revealed only anemia (hemoglobin 10.5 g/dL) with normal chemistry values. Com-
plete stool studies for viral and bacterial pathogens, parasites, and C. difficile toxin were neg-
ative. Computerized tomography of the abdomen showed diffuse thickening of the colon. 
The patient was subsequently evaluated with esophagogastroduodenoscopy and colonos-
copy. 
Initial biopsies taken in January 2016 when the patient was first diagnosed revealed dif-
fuse active colitis with dense neutrophilic infiltrates producing crypt distortion, cryptitis, 
and crypt abscesses consistent with a diagnosis of moderate UC which was consistent at the 
time with a PUCAI score of 60 (Fig. 1). After initial treatment with nightly mesalamine ene-
mas, oral sulfasalazine (500 mg 4 times daily) and short courses of prednisone (40 mg 3 
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times daily for 1 month followed by a taper), there was improvement in the macroscopic 
findings of a colonoscopy performed in August 2016, but with persistent inflammation (Fig. 
2a). The PUCAI score improved from a moderate score of 60 at initial diagnosis to a mild 
score of 30 in August 2016. Biopsy findings from the August 2016 colonoscopy showed im-
provement as well, which correlated with a PUCAI score of 30, but there was still persistent 
chronic inflammation with active cryptitis and crypt distortion as well as marked depletion 
of goblet cells (Fig. 3a). The patient responded slowly to the regimen, but with intermittent 
bouts of abdominal pain and bloody stools. Oral prednisone therapy was restarted in August. 
Dietary recommendations of low fat and low residue were adhered to during this time. Sul-
fasalazine was replaced with oral mesalamine 1.2 g twice daily, but did not appreciably im-
prove symptoms. In November 2016, the patient was started on a nightly course of 5 g SBI (1 
packet EnteraGam®) added to mesalamine. Crampy abdominal symptoms, blood in the 
stools, and diarrhea resolved within 2 months of SBI intake. 
After the addition of SBI to therapy for 2 months (February 2017), colonoscopy revealed 
macroscopic normalization of colonic mucosa (Fig. 2b) and biopsy findings demonstrated 
normal colonic mucosa showing no significant inflammatory activity with restoration of 
crypt architecture correlating with a PUCAI score of <10 (Fig. 3b). The patient had normal 
stool number and consistency, an absence of bleeding and abdominal pain, an absence of 
nocturnal stools, and normal activity levels. Laboratory values of complete blood counts 
revealed normal hemoglobin of 12.6 g/dL and normal serum chemistries. The combination 
of clinical remission of symptoms with normal endoscopic and biopsy findings suggested the 
patient was in “deep remission.” 
Discussion 
This case report supports the important role of SBI as an add-on therapy in the man-
agement of pediatric UC. The classification of SBI as a medical food lends itself to providing a 
unique role in the safe management of UC by perhaps decreasing immune activation via 
binding of microbial components, thereby reducing antigen uptake and release of proin-
flammatory cytokines and chemokines [8–10]. SBI has been shown to help manage adult IBD 
[4–6]. Of note, a case of a female adult with refractory UC responded successfully after 2 
months of oral steroid therapy and SBI exhibiting endoscopic resolution of disease. Her 
Mayo-UC score decreased from grade 2 to grade 0 [4]. She was maintained on a low-dose 
steroid (5 mg per day) and SBI for a year. However, there is limited clinical data to date on 
the use of SBI in pediatric UC. 
There are different outcome measures and definitions of remission in adult and pediat-
ric UC [11]. In adult UC, there are indices to assess disease activity using clinical, endoscopic, 
quality of life, and histological parameters. The Mayo score is one such index and utilizes 
both clinical and endoscopic parameters. In pediatrics, Turner et al. [2] suggest that the 
PUCAI (from NASPGHAN and CDHNF: A Case-Based Monograph on Pediatric IBD [3]) should 
be used as a primary outcome measure. It is best combined with serological or fecal inflam-
matory measures of inflammation, imaging, and/or endoscopy. In PUCAI, 6 weighted clinical 
items (abdominal pain, rectal bleeding, stool consistency, number of stools per 24 h, noctur-
nal stools, and patient activity level) were used to assess disease severity. Total maximum 
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score was 85 with the following score interpretations: severe >65, moderate 35–64, mild 
10–34, remission <10 (Table 1). In clinical practice, colonoscopic findings to confirm remis-
sion are not often used because timing of mucosal healing in relation to the duration of sub-
sequent clinical remission varies. However, it has been shown that mucosal healing assessed 
by macroscopic appearance during endoscopy predicts long-term remission [12, 13]. 
Patient-reported symptoms of clinical remission may predict endoscopic remission, but 
have yet to be shown to predict the duration of remission. The gold standard for any diag-
nostic armamentarium in colitis, however, is tissue diagnosis. There is no agreement on the 
definition of remission in current guidelines, though microscopic or histological healing may 
be a better predictor than the macroscopic appearance or clinical criteria of time to relapse. 
Histological assessment with indicators of acute mucosal inflammation such as crypt ab-
scesses, mucin depletion, or an acute inflammatory cell infiltrate were associated with a 2- to 
3-fold increase in the risk of UC relapse during a 12-month follow-up [13]. The presence of 
dense infiltration of plasma cells in the basal mucosa in patients with quiescent UC has also 
been associated with a 4.5-fold increased risk of relapse. Another parameter often studied in 
the objective measurement of pediatric UC remission is the use of fecal calprotectin. So-
called “deep remission,” the combination of clinical remission, normal endoscopic findings, 
and normal biopsy, is the current goal for all treatments for IBD. Fecal calprotectin in UC has 
a strong negative predictive value for remission [14]. Recently, a decrease in fecal calprotec-
tin from >1,700 to <15 μg/g and induction of clinical remission after a 3-month addition of 
SBI in a therapy-refractory UC case where the patient had a limited response to 6-mer-
captopurine, mesalamine, and VSL#3 was described in a teenage UC patient with a 4-year 
history of relapsing and remitting colitis [7]. 
Our pediatric case presented with moderate UC and had a 1-year history of relapsing 
and remitting colitis. Her standard regimen consisted of oral and rectal suspension of mesal-
amine. She was briefly on corticosteroid therapy for a flare-up of disease activity prior to 
intake of SBI. She had a healthy diet consisting mainly of white meat and vegetables supple-
mented by probiotics, which is in line with the dietary recommendations in the specific car-
bohydrate diet which has been reported to induce remission in pediatric Crohn’s disease and 
UC. In the case presented, photomicrographs of the colonoscopy prior to and after SBI ad-
ministration validate the assertion with findings of endoscopic remission (Fig. 3a, b). After 
addition of SBI to therapy, the PUCAI score also decreased to <10 within 6–8 weeks, sugges-
tive of clinical remission. The biopsy findings in this pediatric case after the addition of SBI 
indicate tissue healing, the third rail in proposed “deep remission” for IBD. It is possible that 
this patient experienced spontaneous remission, but the temporal nature of symptom relief 
combined with endoscopy and biopsy findings make this outcome unlikely. 
EnteraGam® containing SBI has a potential add-on role to standard treatment protocols 
in inducing remission in pediatric UC. The pediatric case described here supports the role of 
immunoglobulins present in SBI that specifically bind to numerous microbe-related inflam-
matory antigens in targeting one of the multifactorial causes of IBD. With the categorization 
of EnteraGam® as a medical food, it does not pose any inherent risk for chronic intake as this 
class of therapeutics requires food-like safety known as generally recognized as safe (GRAS) 
status. Indeed, the FDA has reviewed the safety of SBI and issued a letter of no challenge to 
the protein formulation’s GRAS status [15]. Further research studies are needed to shed light 
on SBI’s mode of interaction with antibiotics, immunomodulators, anti-inflammatory, and 
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biologic agents in the treatment of pediatric IBD. There appears to be promise in the role of 
long-term bovine serum immunoglobulin as add-on therapy in inducing and sustaining re-
mission in pediatric UC. 
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Fig. 1. a Low-power view (10×) of January 2016 colonic mucosal biopsy of the patient showing diffuse 
active colitis with dense neutrophilic infiltrates producing crypt distortion, cryptitis, and crypt abscesses 
(arrow) consistent with the diagnosis of ulcerative colitis. b High-power view (40×) of the same colonic 
biopsy (January 2016) showing dense chronic inflammatory infiltrates of lymphocytes, plasma cells, and 
eosinophils (arrow). (Soriano and Soriano; histopathology by Antonio Alvarez Mendoza, MD.) 
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Fig. 2. Colonoscopy performed in August 2016 prior to SBI administration (a) compared to colonoscopy in 
February 2017 after 2 months of SBI administration (b). 
 
 
 
Fig. 3. a Low-power (10×) biopsy view of colonic mucosa (August 2016 image) showing persistent chronic 
inflammation with active cryptitis, crypt distortion, and marked depletion of goblet cells. Note the persis-
tence of crypt abscess and surface ulcerations (arrow). b February 2017 lower-power (4×) image showing 
no significant inflammatory activity with restoration of crypt architecture. (Soriano and Soriano; histo-
pathology by Antonio Alvarez Mendoza, MD.) 
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Table 1. Pediatric Ulcerative Colitis Activity Index (PUCAI) 
  
  
Item Category/points 
  
  
Abdominal pain No pain = 0 
Pain can be ignored = 5 
Pain cannot be ignored = 10 
    Rectal bleeding None = 0 
Small amount only, in less than 50% of stools = 20 
Small amount with most stools = 20 
Largest amount (50% of the stool content) = 30 
    Stool consistency of most stools Formed = 0 
Partially formed = 5 
Completely unformed = 10 
    Number of stools per 24 h 0–2 = 0 
3–5 = 5 
6–8 = 10 
>8 = 15 
    Nocturnal stools (any episode causing  
wakening) 
No = 0 
Yes = 10 
    Activity level No limitation of activity = 0 
Occasional limitation of activity = 5 
Severe restricted activity = 10 
     Sum of PUCAI (0–85) 
  
  
Disease severity is defined by the following scores: severe, ≥65; moderate, 35–64; mild, 10–34; remission 
(inactive disease), <10. 
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